angiotensin receptor blockers (ARBs) - versus control - for COVID 19 outpatients pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 1.02 [0.02, 52.15]< 10%1 study (1/-)49.7 %NAnot evaluable crucial-
deaths 1.02 [0.02, 52.15]< 10%1 study (1/-)49.7 %NAnot evaluable crucial-
hospitalization 3.16 [0.32, 31.34]< 10%1 study (1/-)16.4 %NAnot evaluable important-
ICU admission 1.02 [0.06, 16.66]< 10%1 study (1/-)49.5 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.